Pharmacology News and Research

Latest Pharmacology News and Research

Researchers use 3-D imaging to identify proteins involved in arterial stiffness

Human arteries - some smaller than a strand of hair - stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process.

10 Jan 2012

Presidio completes PPI-668 Phase 1a study on hepatitis C

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

9 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

Varenicline may reduce smoking rates before people try to quit

Smokers planning to kick the habit may have more success if they begin using a cessation medication several weeks before they actually try to quit.

6 Jan 2012

Scientists identify how dihydromyricetin counteracts acute alcohol intoxication

UCLA researchers have identified how a component of an ancient Chinese herbal anti-hangover medicine called dihydromyricetin, isolated from the plant Hovenia, counteracts acute alcohol intoxication and withdrawal symptoms.

6 Jan 2012

Ipsen, Oncodesign partner to discover and develop LRRK2 kinase inhibitors against PD

Oncodesign, a Drug Discovery company and Oncology pharmacology service provider, and Ipsen, a global specialty-driven pharmaceutical company, announced today that the two companies have entered into a research collaboration to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas.

5 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Alteration in ISG15 pathway triggers breast cancer metastasis

Research led by Shyamal Desai, PhD, Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, has discovered a key change in the body's defense system that increases the potential for breast cancer to spread to other parts of the body.

4 Jan 2012

Scientists identify molecular player critical to proper working of important health proteins

Half the drugs used today target a single class of proteins - and now scientists have identified an important molecular player critical to the proper workings of those proteins critical to our health.

28 Dec 2011

Tyrosine kinases play greater role in mitochondria than previously recognized

Cancer cells tend to take up more glucose than healthy cells, and researchers are increasingly interested in exploiting this tendency with drugs that target cancer cells' altered metabolism.

From Cell Signaling Technology 23 Dec 2011

LincRNAs play key roles during embryonic brain development

Whitehead Institute scientists have identified conserved, long intervening non-coding RNAs (lincRNAs) that play key roles during embryonic brain development in zebrafish. They also show that the human versions of the lincRNAs can substitute for the zebrafish versions, which implies that the functions of these non-coding RNAs have been retained in humans as well as fish.

23 Dec 2011

Botox can have unsuspected 'systemic' effects on muscles

Botulinum neurotoxin type A—better known as Botox—has previously unsuspected 'systemic' effects on muscles other than the ones it's injected into, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

23 Dec 2011

ASCs need to develop policies for management of malignant hyperthermia

As the number of surgical procedures performed outside hospitals continues to increase, ambulatory surgical centers (ASCs) need to develop policies for managing malignant hyperthermia—a rare but serious reaction to anesthetics, according to an expert panel report in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

23 Dec 2011

New way to awaken paternal Ube3a allele linked with Angelman syndrome

Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism.

22 Dec 2011

Researchers map every apparent physical interaction of HIV virus with human cells

In perhaps the most comprehensive survey of the inner workings of HIV, an international team of scientists led by researchers at the University of California, San Francisco has mapped every apparent physical interaction the virus makes with components of the human cells it infects—work that may reveal new ways to design future HIV/AIDS drugs.

22 Dec 2011

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

19 Dec 2011

GSK initiates rhACE2 phase IIa study for Acute Lung Injury

APEIRON Biologics AG announced today that GlaxoSmithKline, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

19 Dec 2011